|
|
|
|
|
|
Sponsored by: |
National Institute on Drug Abuse (NIDA) |
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00000337 |
The purpose of this study is to determine the effects of selegiline on the subjective and physiological effects of cocaine challenge in chronic crack abusers, and to evaluate clinical safety issues pertaining to selegeline, to cocaine and their interaction in a chronic crack dependent population.
Condition | Intervention | Phase |
Cocaine-Related Disorders |
Drug: Selegiline |
Phase I |
Drug Information available for: | Selegiline Selegiline hydrochloride |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | Infusion Laboratory: Protocol 1 - Selegeline |
Estimated Enrollment: | 0 |
Study Start Date: | November 1994 |
To develop a medication for the treatment of cocaine addiction using a medical human physio-neuro-psycho-immunology laboratory setting. To characterize this cocaine abusing population on a variety of psychological and physicologically measures over time from withdrawal through pere and post cocaine administration. To determine the effects of selegeline on the subjective and physiological effects of cocaine challenge in chronic crack abusers. To evaluate clinical safety issues pertaining to selegeline, to cocaine and their interaction in a chronic crack dependent population.
Ages Eligible for Study: | 31 Years to 47 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
M/F, ages 21-50. Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the study and sign informed consent.
Exclusion Criteria:
Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.
United States, California | |||||
Friends Research Institute | |||||
Los Angeles, California, United States, 90025 |
Principal Investigator: | Walter Ling, M.D. | Friends Research Institute, Inc. |
Study ID Numbers: | NIDA-3-0010-2, Y01-3-0010-2 |
First Received: | September 20, 1999 |
Last Updated: | November 3, 2005 |
ClinicalTrials.gov Identifier: | NCT00000337 |
Health Authority: | United States: Federal Government |
|
|
|